ALX Oncology
866 Malcolm Road, Suite 100
Burlingame
CA
94010
United States
Tel: 650-466-7125
Website: http://www.alexotherapeutics.com/
Email: hr@alxoncology.com
118 articles about ALX Oncology
-
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
4/9/2024
ALX Oncology Holdings Inc. reported encouraging clinical data from the ongoing Phase 1/2 investigator-sponsored trial of evorpacept in combination with R2 in patients with indolent and aggressive R/R B-NHL.
-
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/7/2024
ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
-
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
3/5/2024
ALX Oncology Holdings Inc. announced that two clinical abstracts have been accepted for presentation at the American Association for Cancer Research Annual Meeting, which will be held in San Diego from April 5-10, 2024.
-
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
ALX Oncology Holdings Inc. announced today that Jason Lettmann, Chief Executive Officer of ALX Oncology, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8th -11th, 2024.
-
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/13/2023
ALX Oncology Holdings Inc., an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
-
ALX Oncology Announces November 2023 Investor Conference Participation
11/1/2023
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that management will participate in three upcoming investor conferences in November.
-
With recent high-profile failures, experts say safety concerns and a lack of diversification are hindering the field—but still hold out hope for an approval.
-
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - October 10, 2023
10/10/2023
ALX Oncology Holdings Inc., an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants.
-
ALX Oncology Announces Pricing of Public Offering
10/5/2023
ALX Oncology Holdings Inc. today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants. ALX Oncology is selling 7,370,690 shares of common stock.
-
ALX Oncology Announces Proposed Public Offering - October 04, 2023
10/4/2023
ALX Oncology Holdings Inc., an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.
-
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
10/3/2023
ALX Oncology Holdings Inc. announced positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating evorpacept, the Company’s CD47 blocking therapeutic, in combination with trastuzumab, CYRAMZA® and paclitaxel for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer.
-
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
10/2/2023
ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO) today announced the hosting of an investor call and webcast on Tuesday, October 3rd at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer.
-
ALX Oncology Realigns Executive Leadership Team
9/6/2023
ALX Oncology Holdings Inc. today announced that Jason Lettmann, a member of the Board of Directors, will succeed Jaume Pons, Ph.D. as Chief Executive Officer, effective September 6, 2023.
-
The clinical-stage company joins several others in the anti-CD47 space which have dropped studies amid poor results, including Gilead Sciences’ decision late last month to stop a Phase III trial.
-
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
8/10/2023
ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2023, and provided an update on the Company’s portfolio of clinical programs in development.
-
ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer
6/26/2023
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that evorpacept, a next-generation CD47 blocker, has received orphan drug designation (“ODD”) from the European Commission (“EC”) for the treatment of patients with gastric cancer.
-
ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
5/11/2023
ALX Oncology Holdings Inc. reported financial results for the first quarter ended March 31, 2023 and provided clinical development and operational highlights.
-
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer
5/9/2023
ALX Oncology Holdings Inc. announced the initiation of a Phase 2 investigator-sponsored trial of evorpacept, a next generation CD47 blocker, in combination with liposomal doxorubicin and KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with recurrent platinum-resistant ovarian cancer at the UPMC Hillman Cancer Center.
-
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma
4/25/2023
ALX Oncology Holdings Inc. today announced it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate the combination of evorpacept, a next generation CD47 blocker, and SARCLISA.
-
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer
3/13/2023
ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative (“Quantum Leap”) today announced that the first patient has been dosed in the I-SPY-P1-TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer.